Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264473 | 0.96 | ACHE (0.60) | ACHE | |
| SCHEMBL1262984 | 0.86 | ACHE (0.54) | ACHE | |
| SCHEMBL1264152 | 0.84 | ACHE (0.51) | ACHEHDAC6 | |
| SCHEMBL1263029 | 0.83 | HDAC6 (0.48) | HDAC11HDAC6 | |
| SCHEMBL7867652 | 0.81 | ACHE (0.40) | ACHEHDAC11HDAC6 | |
| SCHEMBL1174394 | 0.80 | ACHE (0.53) | ACHE | |
| SCHEMBL1264610 | 0.80 | HDAC6 (0.54) | HDAC11HDAC6 | |
| SCHEMBL1263011 | 0.79 | ACHE (0.51) | ACHE | |
| SCHEMBL1173865 | 0.79 | ACHE (0.53) | ACHE | |
| SCHEMBL1263384 | 0.77 | ACHE (0.52) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | claimed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010151318-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ACHE 3650/4885HDAC11 5/4885HDAC6 1/4885 |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ACHE 3650/4885HDAC11 5/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.